TScan Therapeutics Inc
TCRX1.700USD
+0.080+4.94%
Market hours （ET）Quotes delayed by 15 min
96.20MMarket Cap
LossP/E TTM
More Details of TScan Therapeutics Inc Company
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
Company Info
Ticker SymbolTCRX
Company nameTScan Therapeutics Inc
IPO dateJul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
Number of employees194
Security typeOrdinary Share
Fiscal year-endJul 16
Address830 Winter Street
CityWALTHAM
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02451
Phone18573999500
Websitehttps://www.tscan.com
Ticker SymbolTCRX
IPO dateJul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Chrystal U. Louis
Dr. Chrystal U. Louis
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2022
FY2021
No Data
By RegionUSD
Name
Revenue
Proportion
United States
2.17M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lynx1 Capital Advisors LLC
15.19%
BVF Partners L.P.
9.35%
K2 HealthVentures LLC
6.89%
Adage Capital Management, L.P.
6.69%
Baker Bros. Advisors LP
5.32%
Other
56.56%
Shareholders
Shareholders
Proportion
Lynx1 Capital Advisors LLC
15.19%
BVF Partners L.P.
9.35%
K2 HealthVentures LLC
6.89%
Adage Capital Management, L.P.
6.69%
Baker Bros. Advisors LP
5.32%
Other
56.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.77%
Hedge Fund
23.77%
Venture Capital
19.29%
Investment Advisor/Hedge Fund
12.62%
Research Firm
2.10%
Individual Investor
0.39%
Bank and Trust
0.35%
Private Equity
0.09%
Pension Fund
0.02%
Other
6.59%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
191
48.87M
93.41%
-296.84K
2025Q1
198
46.53M
88.95%
-3.07M
2024Q4
184
47.92M
91.75%
+202.11K
2024Q3
172
45.30M
92.65%
-3.14M
2024Q2
147
48.79M
100.07%
+12.56M
2024Q1
110
39.09M
88.67%
+3.45M
2023Q4
95
36.63M
84.04%
+3.23M
2023Q3
84
33.69M
84.61%
-2.13M
2023Q2
78
32.77M
82.58%
-787.78K
2023Q1
72
14.05M
68.89%
-1.92M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lynx1 Capital Advisors LLC
7.95M
15.19%
+2.59M
+48.32%
May 20, 2025
BVF Partners L.P.
4.89M
9.35%
+1.90M
+63.56%
Mar 31, 2025
K2 HealthVentures LLC
3.60M
6.89%
+2.90M
+414.67%
Dec 31, 2024
Adage Capital Management, L.P.
3.50M
6.69%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
2.78M
5.32%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.61M
4.99%
-57.04K
-2.14%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.5%
-25.79K
-1.08%
Mar 31, 2025
Propel Bio Management, LLC
2.09M
3.99%
--
--
Mar 31, 2025
Pitango Venture Capital
2.08M
3.98%
+2.08M
--
Dec 31, 2023
Checkpoint Capital L.P.
2.02M
3.86%
+261.66K
+14.90%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Simplify Propel Opportunities ETF
2.25%
iShares Health Innovation Active ETF
0.08%
iShares Micro-Cap ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Proshares Ultra Russell 2000
0%
View more
Simplify Propel Opportunities ETF
Proportion2.25%
iShares Health Innovation Active ETF
Proportion0.08%
iShares Micro-Cap ETF
Proportion0.01%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
